Biopharma stocks advanced in the week ended Feb. 5, driven higher by a slew of catalysts. Large-cap pharma earnings, vaccine updates, M&A activity, IPO news flow, and follow-on offerings all served to lift stocks higher.

The stock market hates uncertainty, but the prolonged time to announce a clear winner for this presidential election was ignored by the investors.